PathoLase Inc. (Chico, CA), an emerging biooptics company, says that leading podiatrists in several markets in the US are now treating patients who suffer from toenail fungus (onychomycosis) with its patented PinPointe FootLaser system. "My patients love that fact that I can treat them safely and quickly with no drugs, no anesthesia, no pain and no side effects," said Michael Uro, DPM (doctor of podiatric medicine) of Sacramento, CA.
Led by medical laser pioneer David Harris, PhD, Director of Science & Regulatory Affairs for PathoLase, the company recently brought its patented laser technology to market. The company was formerly known as UVaCide.
"Patients are thrilled that the medical technology industry has finally developed a sophisticated laser system that kills the pathogens that cause toenail fungus quickly and efficiently," said Brian McDowell, DPM, also of Sacramento. "I have had patients call their friends and family from my examining room encouraging them to make their own appointments immediately. We've never seen a public response like this to new drugs or ointments that treat toenail fungus. Nor have we ever had a solution with PinPointe's high rate of success to offer our patients."
PathoLase says its offering is the only existing medical laser technology able to kill the pathogens that cause toenail fungus. The company expects to introduce its product into 20 more major markets in the next several months.
Dr. Michael Uro graduated from Samuel Merritt College (SMC) California School of Podiatric Medicine (CSPM) formerly known as California College of Podiatric Medicine (CCPM), in 1976.